# A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Source: https://onco.cc/trials/nct05570253/  
OnCo record `nct05570253` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of eribulin and evexomostat in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer is a phase 2, randomised interventional study registered as NCT05570253 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 55 participants, started 2022-10-03 and due to reach its primary completion in 2027-10. Interventions recorded: Eribulin; SDX-7320; Placebo. Conditions listed: Breast Cancer; Metastatic Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Male or female with histologically and/or cytologically confirmed diagnosis of triple-negative metastatic breast cancer defined as estrogen and progesterone receptor staining ≤10%; and HER2-negative defined as IHC 0 to 1+ at enrolling institution (note: if IHC is equivocal, non-amplified status by". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05570253
- Phase: 2
- Setting: "A Phase 2, Double Blinded, Randomized Controlled Trial of Evexomostat (SDX-7320) or Placebo in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT05570253: https://clinicaltrials.gov/study/NCT05570253

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Eribulin](https://onco.cc/drugs/eribulin/), [Evexomostat](https://onco.cc/drugs/evexomostat/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05570253.json